Cefotaxime
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Cefotaxime | 1-2g IV Q24H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 455 | 60 | 1 | 15 | 37 | 0.15-0.55 | 2.5-60 | 39-60 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Chodos J, Franck E, Saltzman M, Neu H. Pharmacokinetics of Intravenous Cefotaxime in Patients Undergoing Chronic Hemodialysis. Therapeutic Drug Monitoring 1981; 3, 71-4.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00493
- Glöckner W, Höffler U, Kindler J, Peters G, Sieberth H. Elimination kinetics of cefotaxime in patients with renal insufficiency requiring dialysis. The Journal of antimicrobial chemotherapy 1980; 6 (Suppl A), 219-23.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Ings R, Fillastre J, Godin M, Leroy A, Humbert G. The Pharmacokinetics of Cefotaxime and Its Metabolites in Subjects with Normal and Impaired Renal Function. Reviews Of Infectious Diseases 1982; 4(Supplement), 379-91.
- Matzke G, Abraham P, Halstenson C, Keane W. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clinical pharmacology and therapeutics 1985; 38(1), 31-6.